Vaccine–carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination

Pueyo, Pablo Pastor; Ruberte, E Gambo; Ordás, Jara Gayán; Blanco, Lorena; Figal, Domingo Pascual; Moreira, José María Larrañaga; Barrado, José Javier Gómez; González-Calle, David; Bonet, Luis Almenar; Salinas, Gonzalo Luis Alonso; Pascual, Manuel; Martín, M. Elena; Llinares, Jaume Pons; López, Alejandro Durante; Pérez, Manuel Barreiro; Ocaña, Fernando Candanedo; García, Javier Bautista; Ortega, G; Rodríguez, Fernando Domínguez; Mateo, Virgilio Martínez; Crespo, M. J.; Guzmán, Manuel; Martínez, Laura Jordán; Aboal, Jaime; López, Judit Rodríguez; Santos, Sara Fernández; Martí, Pablo Revilla; Roy, Laura Álvarez; Polo, Juan Carlos; Pinilla, José Manuel García; Vallverdu, Maria Ferre; Bueno, L Garcia; Colomé, Toni Soriano; Diz, Fernando Worner

doi:10.1007/s00392-023-02225-0

Cited by 6 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the rapid rollout of COVID-19 vaccinations, numerous associated and suspected adverse events have been reported nationally and worldwide and their occurrence remains unpredictable. Literature reporting confirmed cases of pericarditis and myocarditis following SARS-CoV-2 mRNA vaccinations [21,[23][24][25][26][27][28][29][30][31]. For example, from the 27.3 million Pfizer-BioNTech (BNT162b2) doses administered in Australia to 2 January 2022, there have been 415 reports of likely myocarditis and 735 reports of likely pericarditis and that from the 1.8 million Moderna (mRNA-1273) doses administered in Australia to 2 January 2022, there have been 40 reports of likely myocarditis and 52 reports of likely pericarditis (COVID-19 vaccine weekly safety report -06-01-2022 | Therapeutic Goods Administration (TGA); accessed on 07.01.2022).…”

Section: Introductionmentioning

confidence: 87%

Circulating Synthetic SARS-CoV-2 Spike Proteins Possibly Contribute to a Transient ACE2 Dysfunction Leading to Rare Cases of Myocarditis after COVID-19 mRNA Vaccination

Devaux,

Colson,

Raoult

et al. 2023

Preprint

View full text Add to dashboard Cite

Myocarditis has been recognized as a possible rare complication of COVID-19 mRNA vaccination. It concerns between one and five vaccinated people per 100,000 in the general population, with increased incidence in adolescent and young adult men. Most often, cases of myocarditis have been reported in the days following the second dose of vaccine mainly in younger male patients. This rare complication of vaccination usually resolves within days or weeks. However, the pathophysiological events responsible for the increase in frequency of myocarditis after COVID-19 vaccination remain unclear. Several recent reports have highlighted that free spike proteins circulating in the blood of patients at high levels appear to play a major role in myocarditis. Here, we review the most relevant data that partly lift the veil on the molecular mechanisms of the induction of myocarditis following mRNA-based COVID-19 vaccination. We hypothesize that a mechanism of molecular mimicry of the viral spike triggers transient dysregulation of angiotensin-converting enzyme 2, leading to increased soluble angiotensin II binding to the transmembrane receptor angiotensin II type I receptor, similar to what is observed during SARS-CoV-2 infection. We suggest to standardize management of suspected cases of mRNA-based COVID-19 vaccine-induced myocarditis, including angiotensin II and spike antigenemia monitoring.

show abstract

Section: Introductionmentioning

confidence: 87%

Circulating Synthetic SARS-CoV-2 Spike Proteins Possibly Contribute to a Transient ACE2 Dysfunction Leading to Rare Cases of Myocarditis after COVID-19 mRNA Vaccination

Devaux,

Colson,

Raoult

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Clinical and serological characterization of acute pleuropericarditis suggests an autoinflammatory pathogenesis and highlights risk factors for recurrent attacks

Kaudewitz,

John,

Meis

et al. 2024

Clin Res Cardiol

View full text Add to dashboard Cite

Purpose We describe the manifestations and course of patients with pleuropericarditis (PP). Serum parameters were analyzed to evaluate the contribution of autoimmune and autoinflammatory mechanisms to PP pathogenesis. Finally, we outline risk factors for recurrent PP attacks. Methods Electronic medical records of the University Hospital Heidelberg were screened for PP diagnosis between the years 2009 and 2021. A total of 164 patients were detected and compared to patients suffering from systemic lupus erythematosus (SLE)-associated PP. Follow-up data were collected until January 2023. Results In 57.3% of a total of 164 PP cases, no trigger was identified (idiopathic PP). The clinical manifestations were similar in subgroups with different triggers (idiopathic, post-cardiac injury and post-infectious). None of the patients in the idiopathic-PP (i-PP) group fulfilled the diagnostic criteria of an autoimmune disease and the i-PP group could be clearly discriminated by clinical, epidemiological and serological means from the control cohort of SLE-associated PP. After a median follow-up of 1048 days, the majority of PP patients (72.7%) had at least one PP relapse. Univariate analyses showed that CRP, SAA (serum amyloid A), troponin T, NT-BNP and post-cardiac injury were negatively correlated, while the presence of fever and an idiopathic trigger were positively correlated with recurrence of PP. Multivariate analyses showed that fever, an idiopathic trigger and low SAA values were risk factors for PP recurrence. Conclusion This study highlights that most cases of PP are idiopathic and PP cases with various triggers have an identical clinical phenotype. Our data suggest that the clinical, epidemiological and serological characteristics of idiopathic PP considerably differ from patients with PP caused by autoimmune disease like SLE. We further demonstrate that PP has a high risk of recurrence and identify factors associated with this risk, allowing for a targeted secondary prophylaxis. Graphical Abstract

show abstract

Azd-1222

2024

Reactions Weekly

View full text Add to dashboard Cite

Vaccine–carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination

Cited by 6 publications

References 20 publications

Circulating Synthetic SARS-CoV-2 Spike Proteins Possibly Contribute to a Transient ACE2 Dysfunction Leading to Rare Cases of Myocarditis after COVID-19 mRNA Vaccination

Circulating Synthetic SARS-CoV-2 Spike Proteins Possibly Contribute to a Transient ACE2 Dysfunction Leading to Rare Cases of Myocarditis after COVID-19 mRNA Vaccination

Clinical and serological characterization of acute pleuropericarditis suggests an autoinflammatory pathogenesis and highlights risk factors for recurrent attacks

Azd-1222

Contact Info

Product

Resources

About